Inhibition of histone deacetylase activity by butyrate - PubMed

Affiliations

• PMID: 12840228
• DOI: 10.1093/jn/133.7.2485S

Review

Inhibition of histone deacetylase activity by butyrate

James R Davie. J Nutr. 2003 Jul.

Abstract

This article reviews the effects of the short-chain fatty acid butyrate on histone deacetylase (HDAC) activity. Sodium butyrate has multiple effects on cultured mammalian cells that include inhibition of proliferation, induction of differentiation and induction or repression of gene expression. The observation that butyrate treatment of cells results in histone hyperacetylation initiated a flurry of activity that led to the discovery that butyrate inhibits HDAC activity. Butyrate has been an essential agent for determining the role of histone acetylation in chromatin structure and function. Interestingly, inhibition of HDAC activity affects the expression of only 2% of mammalian genes. Promoters of butyrate-responsive genes have butyrate response elements, and the action of butyrate is often mediated through Sp1/Sp3 binding sites (e.g., p21(Waf1/Cip1)). We demonstrated that Sp1 and Sp3 recruit HDAC1 and HDAC2, with the latter being phosphorylated by protein kinase CK2. A model is proposed in which inhibition of Sp1/Sp3-associated HDAC activity leads to histone hyperacetylation and transcriptional activation of the p21(Waf1/Cip1) gene; p21(Waf1/Cip1) inhibits cyclin-dependent kinase 2 activity and thereby arrests cell cycling. Pending the cell background, the nonproliferating cells may enter differentiation or apoptotic pathways. The potential of butyrate and HDAC inhibitors in the prevention and treatment of cancer is presented.

Similar articles

• p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.

  Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, Guerra F, Pession A, Ferreri AM. Rocchi P, et al. Oncol Rep. 2005 Jun;13(6):1139-44. Oncol Rep. 2005. PMID: 15870934

• Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.

  Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A. Davis T, et al. Clin Cancer Res. 2000 Nov;6(11):4334-42. Clin Cancer Res. 2000. PMID: 11106251

• The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.

  Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, Seiser C. Lagger G, et al. Mol Cell Biol. 2003 Apr;23(8):2669-79. doi: 10.1128/MCB.23.8.2669-2679.2003. Mol Cell Biol. 2003. PMID: 12665570 Free PMC article.

• Histone deacetylase inhibitors: signalling towards p21cip1/waf1.

  Ocker M, Schneider-Stock R. Ocker M, et al. Int J Biochem Cell Biol. 2007;39(7-8):1367-74. doi: 10.1016/j.biocel.2007.03.001. Epub 2007 Mar 7. Int J Biochem Cell Biol. 2007. PMID: 17412634 Review.

• Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites.

  Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. Sowa Y, et al. Ann N Y Acad Sci. 1999;886:195-9. doi: 10.1111/j.1749-6632.1999.tb09415.x. Ann N Y Acad Sci. 1999. PMID: 10667218 Review.

Cited by

• Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.

  Galmozzi A, Mitro N, Ferrari A, Gers E, Gilardi F, Godio C, Cermenati G, Gualerzi A, Donetti E, Rotili D, Valente S, Guerrini U, Caruso D, Mai A, Saez E, De Fabiani E, Crestani M. Galmozzi A, et al. Diabetes. 2013 Mar;62(3):732-42. doi: 10.2337/db12-0548. Epub 2012 Oct 15. Diabetes. 2013. PMID: 23069623 Free PMC article.

• BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro.

  Mitra R, Bhagavatula ID, Gope R. Mitra R, et al. Ecancermedicalscience. 2012;6:285. doi: 10.3332/ecancer.2012.285. Epub 2012 Dec 20. Ecancermedicalscience. 2012. PMID: 23304241 Free PMC article.

• Age-associated temporal decline in butyrate-producing bacteria plays a key pathogenic role in the onset and progression of neuropathology and memory deficits in 3×Tg-AD mice.

  Chilton PM, Ghare SS, Charpentier BT, Myers SA, Rao AV, Petrosino JF, Hoffman KL, Greenwell JC, Tyagi N, Behera J, Wang Y, Sloan LJ, Zhang J, Shields CB, Cooper GE, Gobejishvili L, Whittemore SR, McClain CJ, Barve SS. Chilton PM, et al. Gut Microbes. 2024 Jan-Dec;16(1):2389319. doi: 10.1080/19490976.2024.2389319. Epub 2024 Aug 25. Gut Microbes. 2024. PMID: 39182227 Free PMC article.

• Quantitative assessment of the impact of the gut microbiota on lysine epsilon-acetylation of host proteins using gnotobiotic mice.

  Simon GM, Cheng J, Gordon JI. Simon GM, et al. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11133-8. doi: 10.1073/pnas.1208669109. Epub 2012 Jun 25. Proc Natl Acad Sci U S A. 2012. PMID: 22733758 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal